These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 23672237)
1. Cilostazol prevents foot ulcers in diabetic patients with peripheral vascular disease. de Franciscis S; Gallelli L; Battaglia L; Molinari V; Montemurro R; Stillitano DM; Buffone G; Serra R Int Wound J; 2015 Jun; 12(3):250-3. PubMed ID: 23672237 [TBL] [Abstract][Full Text] [Related]
2. Cilostazol treatment of claudication in diabetic patients. Rendell M; Cariski AT; Hittel N; Zhang P Curr Med Res Opin; 2002; 18(8):479-87. PubMed ID: 12564659 [TBL] [Abstract][Full Text] [Related]
3. [Cilostazol improves the quality of life and lower-limb functional capacity also in diabetic patients]. Farkas K; Kolossváry E; Járai Z Orv Hetil; 2020 Sep; 161(38):1637-1645. PubMed ID: 32924968 [TBL] [Abstract][Full Text] [Related]
4. Reduction of remnant lipoprotein cholesterol concentrations by cilostazol in patients with intermittent claudication. Wang T; Elam MB; Forbes WP; Zhong J; Nakajima K Atherosclerosis; 2003 Dec; 171(2):337-42. PubMed ID: 14644405 [TBL] [Abstract][Full Text] [Related]
5. Effects of cilostazol on arterial wound healing: a retrospective analysis. Resnick KA; Gordon IL Ann Vasc Surg; 2014 Aug; 28(6):1513-21. PubMed ID: 24561209 [TBL] [Abstract][Full Text] [Related]
6. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Beebe HG; Dawson DL; Cutler BS; Herd JA; Strandness DE; Bortey EB; Forbes WP Arch Intern Med; 1999 Sep; 159(17):2041-50. PubMed ID: 10510990 [TBL] [Abstract][Full Text] [Related]
7. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Strandness DE; Dalman RL; Panian S; Rendell MS; Comp PC; Zhang P; Forbes WP Vasc Endovascular Surg; 2002; 36(2):83-91. PubMed ID: 11951094 [TBL] [Abstract][Full Text] [Related]
8. Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease. Bramer SL; Forbes WP; Mallikaarjun S Clin Pharmacokinet; 1999; 37 Suppl 2():1-11. PubMed ID: 10702882 [TBL] [Abstract][Full Text] [Related]
9. The effect of withdrawal of drugs treating intermittent claudication. Dawson DL; DeMaioribus CA; Hagino RT; Light JT; Bradley DV; Britt KE; Charles BE Am J Surg; 1999 Aug; 178(2):141-6. PubMed ID: 10487267 [TBL] [Abstract][Full Text] [Related]
10. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. Money SR; Herd JA; Isaacsohn JL; Davidson M; Cutler B; Heckman J; Forbes WP J Vasc Surg; 1998 Feb; 27(2):267-74; discussion 274-5. PubMed ID: 9510281 [TBL] [Abstract][Full Text] [Related]
11. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Dawson DL; Cutler BS; Hiatt WR; Hobson RW; Martin JD; Bortey EB; Forbes WP; Strandness DE Am J Med; 2000 Nov; 109(7):523-30. PubMed ID: 11063952 [TBL] [Abstract][Full Text] [Related]
12. A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. Brass EP; Cooper LT; Morgan RE; Hiatt WR J Vasc Surg; 2012 Feb; 55(2):381-389.e1. PubMed ID: 22119244 [TBL] [Abstract][Full Text] [Related]
13. Cilostazol: treatment of intermittent claudication. Reilly MP; Mohler ER Ann Pharmacother; 2001 Jan; 35(1):48-56. PubMed ID: 11197586 [TBL] [Abstract][Full Text] [Related]
14. A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication. Pande RL; Hiatt WR; Zhang P; Hittel N; Creager MA Vasc Med; 2010 Jun; 15(3):181-8. PubMed ID: 20385711 [TBL] [Abstract][Full Text] [Related]
15. Clinical manifestation of atherosclerotic peripheral arterial disease and the role of cilostazol in treatment of intermittent claudication. Grouse JR; Allan MC; Elam MB J Clin Pharmacol; 2002 Dec; 42(12):1291-8. PubMed ID: 12463722 [TBL] [Abstract][Full Text] [Related]
16. Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. Lee TM; Su SF; Tsai CH; Lee YT; Wang SS Clin Sci (Lond); 2001 Sep; 101(3):305-11. PubMed ID: 11524048 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication. Soga Y; Yokoi H; Kawasaki T; Nakashima H; Tsurugida M; Hikichi Y; Nobuyoshi M J Am Coll Cardiol; 2009 Jan; 53(1):48-53. PubMed ID: 19118724 [TBL] [Abstract][Full Text] [Related]
18. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). Hiatt WR; Money SR; Brass EP J Vasc Surg; 2008 Feb; 47(2):330-336. PubMed ID: 18155871 [TBL] [Abstract][Full Text] [Related]
19. Effect of cilostazol prescribed in a pragmatic treatment program for intermittent claudication. Lee C; Nelson PR Vasc Endovascular Surg; 2014 Apr; 48(3):224-9. PubMed ID: 24399131 [TBL] [Abstract][Full Text] [Related]
20. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. Regensteiner JG; Ware JE; McCarthy WJ; Zhang P; Forbes WP; Heckman J; Hiatt WR J Am Geriatr Soc; 2002 Dec; 50(12):1939-46. PubMed ID: 12473004 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]